Cancers in renal transplant recipients

被引:211
作者
Penn, I [1 ]
机构
[1] Univ Cincinnati, Dept Surg, Div Transplantat, Cincinnati, OH 45267 USA
来源
ADVANCES IN RENAL REPLACEMENT THERAPY | 2000年 / 7卷 / 02期
关键词
transplantation; immunosuppression; cancer; lymphoma; Kaposi's sarcoma;
D O I
10.1053/rr.2000.5269
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Data regarding posttransplant cancers are reviewed from the Cincinnati Transplant Tumor Registry (CTTR) and from the literature. The CTTR has data on 9,688 types of cancer that developed in 9,032 renal allograft recipients. The predominant tumors are lymphomas and lymphoproliferations (PTLD). carcinomas of the skin and lips, carcinomas of the vulva and perineum, in situ carcinomas of the cervix of the uterus. Kaposi's sarcoma (KS), hepatocellular carcinomas, renal carcinomas, and various sarcomas (excluding KS). Prominent features of the PTLD cases are their high incidence, frequent involvement of extranodal sites, a marked predilection for the brain, and frequent involvement of the allograft by tumor. Skin cancers also present unusual features, a remarkable high frequency of KS, reversal of the ratio of basal cell carcinomas to squamous cell carcinomas that is seen in the general population, the young age of the patients, the high incidence of multiple tumors (in 44% of patients), and the aggressive behavior of some squamous cell carcinomas. Cancers of the vulva and perineum occur at a much younger age than in the general population and are preceded by a history of condyloma acuminatum in over 57% of cases. Reduction or cessation of immunosuppressive therapy is of value in some patients with PTLD or KS but carries the risk of allograft rejection. (C) 2000 by the National Kidney Foundation, Inc.
引用
收藏
页码:147 / 156
页数:10
相关论文
共 41 条
[1]  
al-Sulaiman M H, 1994, Transplant Sci, V4, P46
[2]  
BARR BBB, 1989, LANCET, V1, P124
[3]  
BARRETT WL, 1993, CANCER, V72, P2186, DOI 10.1002/1097-0142(19931001)72:7<2186::AID-CNCR2820720720>3.0.CO
[4]  
2-2
[5]   Relation between HLA antigens and skin cancer in renal transplant recipients in Queensland, Australia [J].
Bavinck, JNB ;
Claas, FHJ ;
Hardie, DR ;
Green, A ;
Vermeer, BJ ;
Hardie, IR .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1997, 108 (05) :708-711
[6]   RELATION BETWEEN SKIN-CANCER AND HLA ANTIGENS IN RENAL-TRANSPLANT RECIPIENTS [J].
BAVINCK, JNB ;
VERMEER, BJ ;
VANDERWOUDE, FJ ;
VANDENBROUCKE, JP ;
SCHREUDER, GMT ;
THOROGOOD, J ;
PERSIJN, GG ;
CLAAS, FHJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (12) :843-848
[7]  
BAVINCK JNB, 1995, HUM EXP TOXICOL, V14, P98
[8]   THERAPY FOR TRANSPLANT-RELATED LYMPHOPROLIFERATIVE DISEASES [J].
BENKERROU, M ;
DURANDY, A ;
FISCHER, A .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1993, 7 (02) :467-475
[9]   CANCER RISK AFTER RENAL-TRANSPLANTATION IN THE NORDIC COUNTRIES, 1964-1986 [J].
BIRKELAND, SA ;
STORM, HH ;
LAMM, LU ;
BARLOW, L ;
BLOHME, I ;
FORSBERG, B ;
EKLUND, B ;
FJELDBORG, O ;
FRIEDBERG, M ;
FRODIN, L ;
GLATTRE, E ;
HALVORSEN, S ;
HOLM, NV ;
JAKOBSEN, A ;
JORGENSEN, HE ;
LADEFOGED, J ;
LINDHOLM, T ;
LUNDGREN, G ;
PUKKALA, E .
INTERNATIONAL JOURNAL OF CANCER, 1995, 60 (02) :183-189
[10]  
BLOHME I, 1985, TRANSPLANTATION, V39, P23